期刊文献+

多色探针熔解曲线法应用于别嘌呤醇不良反应相关基因HLA-B* 58∶01的检测 被引量:3

Rapid detection of HLA-B* 58∶01 gene based on multiplex melting curve analysis for the monitoring of adverse drug reaction caused by allopurinol
下载PDF
导出
摘要 目的评价多色探针熔解曲线法(MMCA)在别嘌呤醇不良反应相关的HLA-B* 58∶01基因检测中的应用。方法收集1147(人)份厦门地区无偿献血者的外周静脉血标本,提取全基因组DNA后,按双盲对照试验,分别应用HLA序列分型(HLA-SBT)测序法和MMCA法检测各标本的HLA-B* 58∶01基因,比较2种检测方法的符合率。结果采用HLA-SBT测序法与MMCA法在1 147人份献血者标本中检出的HLA-B* 58∶01阳性及阴性标本均相同,分别为213和934例,符合率为100%(1 147/1 147);本组厦门地区献血人群的HLA-B* 58∶01携带率为18.57%(213/1147)。结论 MMCA法用于HLA-B* 58∶01基因检测简便、快速、灵敏度高、特异性强。 Objective Evaluation of the HLA-B* 58∶01 gene detection based on multiplex melting curve analysis(MMCA) for the monitoring of adverse drug reaction caused by allopurinol. Methods We collected 1147 peripheral blood samples from donators in Xiamen City. DNA was extracted from the samples and a blind test was then performed to validate the consistency between human leukocyte antigens sequence-based typing(HLA-SBT) assay and MMCA assay for HLA-B* 58∶01 gene. Results In this study,213 cases were identified positive and 934 were negative by HLA-SBT assay and MMCA assay. The overall agreement between HLA-SBT assay and MMCA assay is 100%(1147/1147) for HLA-B* 58∶01 gene detection. The percentage of positive samples was 18. 57 %(213/1 147). Conclusion MMCA assay is a convenient and quick method with high sensitivity and excellent specificity and thus promises a powerful tool for the clinical diagnosis of HLA-B* 58∶01 gene.
作者 裴斌 郭晓彤 冉鹏 黄秋英 洪素云 钟雪婷 李庆阁 PEI Bin1, GUO Xiaotong2, RAN Peng1, HUANG Qiuying2, HONG Suyun1, ZHONG Xuet- ing2, LI Qingge2(1.Xiamen Blood Center,Xiamen 361004, China ; 2. School of Life Sciences,Xiamen University)
出处 《中国输血杂志》 CAS 2018年第1期37-40,共4页 Chinese Journal of Blood Transfusion
关键词 多色探针熔解曲线法 别嘌呤醇不良反应 HLA-B* 58∶01基因 痛风 multiplex melting curve analysis (MMCA) Adverse drug reaction caused by a11opurinol HLA-B* 58:01gene
  • 相关文献

参考文献1

二级参考文献3

  • 1Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1431-1446.
  • 2Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis [J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1447-1461.
  • 3孟济明,邹和建.风湿病学发展的点滴思考[J].内科理论与实践,2011,6(5):329-330. 被引量:7

共引文献57

同被引文献11

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部